Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report

Benzer Materyaller

• Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC
  Yazar:: Lianxi Song, MD, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-12-01)
• Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
  Yazar:: Caicun Zhou, MD, PhD, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-09-01)
• Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
  Yazar:: S. G. Bagrova, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-12-01)
• Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement
  Yazar:: Milda Mikalonytė, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-06-01)
• Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
  Yazar:: Naoko Imanishi, ve diğerleri
  Baskı/Yayın Bilgisi: (2018-03-01)